Ennov has run on the same founding CEO for 27 years, so the appointment of Dr. Oxana Pickeral to replace Olivier Pâris carries weight beyond a routine leadership change. Pâris co-founded the company in 1999 and built it to €58.4 million in 2024 revenue, averaging 20 percent annual growth over the five years through 2025. Handing that over to an incoming chief is a genuine inflection, not a housekeeping move, and what Pickeral does with the product roadmap in the next 12 months will say more than the announcement itself.
Pâris moves to Ennov’s board, which keeps him in the room without keeping him at the controls. That structure is common in founder transitions and gives Pickeral room to operate while preserving institutional knowledge, though it also means the board dynamic will be unusually loaded at first. The September 9 announcement offers no detail on Pickeral’s prior role or where she comes from, so her specific background in clinical operations or regulatory technology remains unconfirmed from available sources.
The timing is not accidental. The EU Clinical Trials Regulation hit a hard compliance deadline in January 2025, requiring all trials previously approved under the older directive to migrate to the CTR framework. That pressure accelerated demand for platforms that unify regulatory, clinical, and pharmacovigilance workflows under one audit trail. Ennov’s pitch is exactly that unified stack, and a new CEO inherits both the growth opportunity and the obligation to execute against customers who are mid-migration and impatient.
The number to watch is whether revenue growth holds above that 20 percent average under new leadership. Ennov went from €33.4 million in 2022 to €58.4 million in 2024, a 75 percent gain in two years. That pace is difficult to sustain organically, which means Pickeral’s first visible strategic choice will likely be whether to push deeper into existing accounts, expand geographically, or pursue acquisitions. Her answer to that question is the real story.
Source link: https://en.ennov.com/news/announcement/ennov-appoints-oxana-pickeral-as-chief-executive-officer/
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
